Drug Discovery World

APRIL 6, 2023

Granular Therapeutics, a UK-based biotech company specialising in precision biologic therapies for treating mast cell driven disorders, announced clinical candidate selection for its lead programme which has demonstrated promising results in initial preclinical studies. It has developed a pipeline that selectively targets mast cells.

Disease 130

Disease Clinical Development Therapies Drugs 130

Drug Discovery World

FEBRUARY 15, 2024

DDW Editor Reece Armstrong speaks to Tracy M Woody , President and Chief Executive Officer of Cessation Therapeutics, about the company’s goal to develop an antibody therapy to prevent fentanyl overdoses. The American Medical Association (AMA) acknowledged that alcohol and drug dependence are diseases, a quarter of a century ago.

Therapies 147

Therapies FDA Approval FDA Government 147

Drug Discovery World

NOVEMBER 24, 2022

DDW’s Diana Spencer asks what will be needed for Europe to compete in the growing global market for advanced therapies. . In terms of ATMPs, other countries are ramping up support for these innovative therapies. China has meanwhile grown its share from 1% to 8%. . Boosting digital capabilities.

Therapies 245

Therapies Clinical Trials Pharmaceuticals Government 245

Drug Discovery World

MAY 20, 2024

BenevolentAI’s strategic collaboration with AstraZeneca began in 2019, and originally focused on discovering potential new treatments for idiopathic pulmonary fibrosis (IPF) and chronic kidney disease (CKD). The collaboration was expanded in January 2022 to two new disease areas, heart failure and systemic lupus erythematosus (SLE).

Disease 147

Disease Therapies Treatment Marketing 147

Drug Discovery World

JULY 11, 2022

David Lewandowski, Business Director of Cell & Gene Therapy at Azenta Life Sciences, explains how efficient sample management can help to work efficiently and bring therapies to market faster. The global cell and gene therapy (CGT) market reached a value of ~$4 billion in 2020 and is expected to grow to ~$34 billion by 2030 1.

Therapies 130

Therapies Clinical Trials Production Trials 130

BioPharma Drive: Drug Pricing

AUGUST 28, 2023

The treatment, developed by a biotech Bayer acquired in 2019, appeared safe in a small trial and showed signs of an effect on disease progression.

Therapies 98

Therapies Trials Treatment Disease 98

Drug Target Review

AUGUST 29, 2024

What potential advantages does the CD5 modulation strategy offer over traditional CAR-T therapies? MR : Chimeric antigen receptor T-cell (CAR-T) therapy is very effective in treating patients with B-cell lymphoma, leukemia, and multiple myeloma, where we have six FDA-approved drugs.

Therapies 59

Therapies Treatment Engineering Molecular Biology 59

Drug Discovery World

SEPTEMBER 4, 2024

The Functional Genomics Centre was established in 2019 to explore the function and interaction of genes and proteins in cancer and create sophisticated models of the disease for research. Rachel Grimley, SVP Drug Discovery, Cancer Research Horizons, added: “I am delighted to see the next steps for this important partnership.

Research 130

Research Therapies Disease Drugs 130

Elrig

APRIL 11, 2024

One of the great highlights of a:head’s work has been the ability to observe disease-specific phenotypes and profile clinically used therapeutics for their ability to alter neuronal network activity. The post How to develop drugs for neurological diseases | Insights from Josh Bagley first appeared on ELRIG.

Disease 59

Disease Drugs Regulations Therapies 59

Drug Discovery World

FEBRUARY 20, 2024

With capacity for up to 60 research scientists and employees, the company says the site will play a role in helping to drive innovation in the UK life sciences sector, with the ambition of bringing forward new medicines for patients living with inflammatory diseases. Gilead acquired MiroBio, an Oxford-backed research company, in 2022.

Science 130

Science Research Laboratories Disease 130

The Pharma Data

JANUARY 25, 2021

a biotechnology company developing cell and gene therapy treatments for patients suffering from vascular disease, today announced that it raised up to $5.5M that will lead clinical testing of a novel gene therapy for a serious vascular disease in Europe. MIAMI, Jan. 25, 2021 (GLOBE NEWSWIRE) — Ambulero, Inc. ,

Therapies 52

Therapies Disease Licensing Licensing 52

Drug Discovery World

SEPTEMBER 14, 2023

Patients with mUC, including FGFR-driven tumours, face a particularly poor prognosis and the need for innovative therapies remains high. Patients with mUC, including FGFR-driven tumours, face a particularly poor prognosis and the need for innovative therapies remains high. N Engl J Med 2019; 381(4):338-348. Fernandez E, et al.

Treatment 130

Treatment Clinical Pharmacology FDA Approval Therapies 130

Drug Discovery World

JULY 15, 2022

Pharmaceutical company Transpire Bio will work alongside drug delivery provider Recipharm to develop two inhaled medicines for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD).? . Asthma is thought to affect over 300 million people and in 2019 caused 455,000 deaths 1. million people dying from the condition.

Pharmaceutical Companies 130

Pharmaceutical Companies Therapies Production Treatment 130

Broad Institute

JULY 10, 2024

A three-drug cocktail known as Trikafta has greatly improved patient quality of life since its development in 2019, but can cause cataracts and liver damage and must be taken daily at a cost of about $300,000 per year. There are more than 2,000 known variants of the CFTR gene, 700 of which cause disease.

Engineering 145

Engineering Packaging DNA Treatment 145

PLOS: DNA Science

OCTOBER 12, 2023

In the final chapter of my 2012 book The Forever Fix: Gene Therapy and the Boy Who Saved It , I predicted that the technology would soon expand well beyond the rare disease world. Gene therapy clearly hasn’t had a major impact on health care, offering extremely expensive treatments for a few individuals with rare diseases.

Therapies 69

Therapies Immune Response DNA Virus 69

Drug Discovery World

NOVEMBER 1, 2022

Its snapshot report aimed to provide both an overview of the sector in Australia to determine how the sector has changed since this data was collected in 2017 and 2019 2. . The number of employees behind our biotech companies has also expanded, increasing 21% compared with 2019 from approximately 87,397 people in 2019 to 105,569 in 2022.

Drugs 130

Drugs Science Therapies Clinical Trials 130

Advarra

AUGUST 16, 2022

A rare, or orphan, disease by definition affects a small percentage of the population — fewer than 200,000 people in the U.S. But the numbers add up, and taken together, rare diseases impact an estimated 30 million Americans. Since then, the FDA has significantly changed its approach to rare and orphan diseases.

Disease 52

Disease Clinical Trials FDA Approval FDA 52

Drug Discovery World

NOVEMBER 20, 2023

Biologics represents the fastest-growing sector of the pharmaceutical industry, with hundreds of therapies approved in recent years 3,4. mRNA vaccines and antibody therapies in particular are promising areas that are already having significant impact across the healthcare industry, with enormous potential to address unmet medical needs.

DNA 173

DNA Engineering Vaccine Therapies 173

Drug Discovery World

SEPTEMBER 27, 2023

The therapy is now recommended within an NHS setting for the treatment of adults with newly diagnosed MM where an autologous stem cell transplant (ASCT) is unsuitable. Seven years of trial data DLd is licensed and has been available for use in Europe since 2019.

Regulations 130

Regulations Licensing Licensing Therapies 130

Drug Target Review

SEPTEMBER 25, 2024

Most targeted cancer therapies used today operate by inhibiting targets along well-known oncogenic signalling cascades. The reactivation of oncogenic signalling upstream or downstream of the driving oncogene is a well-studied source of resistance to targeted cancer therapies.

Small Molecule 105

Small Molecule Regulations Therapies Treatment 105

Drug Discovery World

AUGUST 14, 2023

Lung-I Cheng, Vice President and Head of Cell & Gene Therapy Service Line at AmerisourceBergen, and Cori Gorman, Senior Director of CMC and Regulatory Affairs at Biopharma Excellence, offer advice on navigating the different and sometimes contradictory regulatory requirements in the US and EU. billion in 2020 to $15.5

Marketing 130

Marketing DNA Therapies FDA 130

The Pharma Data

JUNE 1, 2022

The United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to efanesoctocog alfa (BIVV001) for the treatment of people with hemophilia A, a rare and life-threatening bleeding disorder, based on data from the pivotal XTEND-1 P hase 3 stud y.

Therapies 52

Therapies FDA Science Treatment 52

The Pharma Data

JULY 2, 2023

The new approach in cancer therapy with innovative mechanism-of-action for ferroptosis induction A team of researchers led by Dr. Marcus Conrad from Helmholtz Munich discovered a novel anti-cancer drug, called icFSP1, which sensitizes cancer cells to ferroptosis. Source link: [link]

Therapies 40

Therapies Small Molecule Pharmacokinetics Disease 40

Drug Discovery World

JANUARY 29, 2024

Studies have shown that combination therapy with this phage and an antibiotic eradicates many dormant germs in pure culture and in a mouse model. For the first time, ETH Zurich researchers in Switzerland have isolated a bacteriophage from rotting plant material that can attack and kill bacteria in a dormant state.

Virus 130

Virus Hospitals Treatment Research 130

The Pharma Data

MAY 31, 2022

the completion of enrollment of its Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson’s disease (PD). of BRT-DA01 in patients with Parkinson’s disease.?. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore lost function.

Trials 52

Trials Disease Clinical Trials Engineering 52

The Pharma Data

JANUARY 12, 2021

In December, life sciences giant Bayer launched a cell and gene therapy platform within its pharmaceutical division in order to become a leading company within a rapidly emerging and evolving field that offers the potential of life-saving therapies. Photo courtesy of Bayer.

Therapies 52

Therapies Licensing Licensing Pharmaceuticals 52

Drug Discovery World

SEPTEMBER 26, 2022

The approval by the European Commission was based on results from the Pathfinder clinical trial programme, which included the pivotal Navigator Phase III trial in which Tezspire demonstrated superiority across every primary and key secondary endpoint in patients with severe asthma, compared to placebo, when added to standard therapy.

Clinical Trials 130

Clinical Trials Trials Disease Production 130

The Pharma Data

JANUARY 17, 2021

18, 2021 /PRNewswire/ — Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Lonza announced today their agreement in support of ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease (SCD). NEW YORK , Jan.

Disease 52

Disease Trials Treatment Clinical Trials 52

The Pharma Data

APRIL 19, 2022

Kite’s Global CAR T-Cell Therapy Manufacturing Network Increasing Capacity by 50% to Meet Patient Demand for New Cancer Therapies. — Scalable and Adaptable Facility Provides Flexibility for Current and Future Cell Therapy Innovation. The site will produce Kite’s FDA approved CAR T-cell therapy used to treat blood cancer.

FDA Approval 52

FDA Approval Therapies FDA Hospitals 52

Drug Target Review

JUNE 9, 2023

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

The Pharma Data

OCTOBER 26, 2020

Food and Drug Administration (FDA) has approved EYSUVIS for the short-term treatment of dry eye disease. . adults have been diagnosed with dry eye disease, a chronic, episodic, multifactorial disease. It also increases your risk for inflamed cornea, cornea eye disease, corneal ulcers and injuries, and eye infections. .

FDA 52

FDA Disease Treatment FDA Approval 52

The Pharma Data

OCTOBER 26, 2020

The agreement covers the gene therapy program targeting OTOF (OTOF-GT), the gene encoding the otoferlin protein. The agreement covers the gene therapy program targeting OTOF (OTOF-GT), the gene encoding the otoferlin protein. Mutations in OTOF lead to severe or profound congenital hearing loss. About Sensorion.

Production 52

Production Therapies Virus Packaging 52

Conversations in Drug Development Trends

FEBRUARY 22, 2023

Rare Disease Day on February 28th is a chance for rare disease communities to come together as one and join in conversation with stakeholders searching for treatments, raising money to support research, and changing the way healthcare and governments interact with patients. In my case, my daughter Iris has GM1 gangliosidosis.

Disease 52

Disease Clinical Trials Trials Treatment 52

Drug Target Review

SEPTEMBER 4, 2023

There have been several studies that have reported the ability of infectious disease agents to be drug resistant. Infectious agent includes bacteria, virus, fungi, and parasites, and they are capable of causing disease in a living organism. They could be spread by physical contact, airborne, waterborne, foodborne, or vector-borne.

Drugs 111

Drugs RNA DNA Disease 111

Drug Discovery World

APRIL 11, 2023

2019 May 23;380(21):2082]. Elevated Expression of IL-33 and TSLP in the Airways of Human Asthmatics In Vivo: A Potential Biomarker of Severe Refractory Disease. The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending AstraZeneca’s Tezspire (tezepelumab). N Engl J Med. Li Y, et al.

Treatment 246

Treatment Clinical Trials Trials Science 246

The Pharma Data

DECEMBER 2, 2020

Based on the Phase 2 study findings to date, marstacimab may have the potential to offer improved bleed control via subcutaneous injection and potentially eliminate the need for prophylactic factor replacement, providing an enhanced treatment option compared to factor replacement therapy.”. In September 2019, the U.S. About Hemophilia.

Therapies 52

Therapies Treatment Disease Clinical Trials 52

Drug Discovery World

MAY 6, 2024

Amsterdam: The centre of European life sciences As a result of the UK withdrawing from the EU, in 2019 the EMA headquarters was moved from London to Amsterdam. The company is now investigating a promising gene therapy for Huntingdon’s disease in a Phase I/II trial, with patients already showing signs of preserved neurological function.

Drugs 147

Drugs Science Molecular Biology Clinical Trials 147